Basis of Presentation and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of customers representing 10% or more of revenues

The following table sets forth customers who represented 10% or more of our total revenues for the three and nine months ended September 30, 2016 and 2015:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
AmerisourceBergen Drug Corporation	20	%	28	%	22	%	25	%
Caremark LLC (Specialty Pharmacy)	10	%	<10	%	10	%	—	%
McKesson Corporation	<10	%	13	%	<10	%	11	%

Schedule of customers representing greater than 10% of accounts receivable balances

Customers which represented greater than 10% of our accounts receivable balance as of September 30, 2016 and December 31, 2015 were as follows:



	September 30, 2016		December 31, 2015
AmerisourceBergen Drug Corporation	12	%	43	%
Caremark LLC (Specialty Pharmacy)	10	%	<10	%

Analysis of U.S. product sales allowances and accruals

Our U.S. product sales, which primarily represented revenues from Makena and Feraheme for the three and nine months ended September 30, 2016 and 2015, were offset by provisions for allowances and accruals as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Gross U.S. product sales	$	201,303	$	145,131	$	530,076	$	407,238
Provision for U.S. product sales allowances and accruals:
Contractual adjustments	61,504		41,851		161,023		116,236
Governmental rebates	24,022		14,363		60,729		40,018
Total provision for U.S. product sales allowances and accruals	85,526		56,214		221,752		156,254
U.S. product sales, net	$	115,777	$	88,917	$	308,324	$	250,984